Clinical trials of IL-17 inhibitors for the treatment of psoriasis, psoriathis arthritis, ankylosing spondilitis, and rheumatoid arthritis--namely ixekizumab, secukinumab, and brodalumab—resulted in newly diagnosed inflammatory bowel disease secondary to the use of these agents [58,59]. Here, IL17A is linked to inflammatory bowel disease.